Azacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma
NCT06190067
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
40
Enrollment
OTHER
Sponsor class
Conditions
Relapsed Classic Hodgkin Lymphoma
Refractory Classic Hodgkin Lymphoma
Interventions
DRUG:
Azacitidine Plus PD-1 therapy
Sponsor
Navy General Hospital, Beijing